Hatchtech Pty. Ltd. is an Australian specialty pharmaceutical company developing technology for the control of invertebrate pests. The Company’s lead product is Xeglyze™, a novel, next generation prescription head lice product in development that aims to overcome the frustrating, costly and inconvenient cycles of retreatment for head lice infestation currently experienced by children and their parents.

Xeglyze™ is a topical lotion containing an inhibitor of metal dependent targets that are involved in all stages of the louse lifecycle from egg to adult. A substantial body of scientific data has established its mode of action, and preclinical and clinical studies have evaluated the efficacy and safety of Xeglyze™.

Hatchtech, which was founded in 2001 by Dr Vern Bowles at the University of Melbourne, is securely financed by a consortium of specialist venture capitalists and is located in Melbourne, Australia.

 

Latest News

Aug 03, 2020 Xeglyze FDA Approval

Sep 14, 2015 Commercialisation Deal and NDA Filed

Sep 02, 2014 Hatchtech Announces Successful Phase 3 Results

Oct 31, 2013 Hatchtech Completes $12.6m Capital Raise, Secures Funds for Phase III and NDA Submission